Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifileucel - Iovance Biotherapeutics

Next Previous
X
Search
Drug Profile

Lifileucel - Iovance Biotherapeutics

Alternative Names: AMTAGVI; Autologous TILs - Iovance Biotherapeutics; Contego™ - Iovance Biotherapeutics; LN-144; Tumour infiltrating lymphocytes - Iovance Biotherapeutics

Latest Information Update: 15 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genesis Biopharma
  • Developer Iovance Biotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Malignant melanoma
  • Phase II Endometrial cancer
  • Phase I Solid tumours; Uveal melanoma

Most Recent Events

  • 07 Nov 2024 The European Medicines Agency announces intention to approve MAA for Malignant melanoma in the European Union in the second half of 2025
  • 07 Nov 2024 The Health Canada announces intention to approve MAA for Malignant melanoma in Canada in mid- 2025
  • 07 Nov 2024 The Medicines and Healthcare products Regulatory Agency announces intention to approve MAA for Malignant melanoma in the United Kingdom in the first half of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top